Draft:Peter Fecci
 | Review waiting, please be patient.
This may take 2–3 weeks or more, since drafts are reviewed in no specific order. There are 882 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article.HRShami (talk)
Peter Edward Fecci | |
|---|---|
| Occupation(s) | Neurosurgeon and academic |
| Academic background | |
| Education | Bachelor of Science Doctor of Medicine Doctor of Philosophy |
| Alma mater | Cornell University Duke University |
| Academic work | |
| Institutions | Duke University University of Colorado School of Medicine |
Peter Edward Fecci is a neurosurgeon and academic. He is a professor of neurosurgery and pathology at Duke University School of Medicine.
Fecci's research has focused on brain tumor immunology and immunotherapy, and T cell dysfunction in glioblastoma and other intracranial cancers. He has received the Synaptive Preuss Award from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).
Education
[edit]Fecci received his Bachelor of Science degree from Cornell University, followed by a Doctor of Medicine and Doctor of Philosophy from Duke University. He also completed a Neurosurgical residency at Massachusetts General Hospital.[1]
Career
[edit]Fecci worked at Duke University as an associate professor of Neurosurgery, Immunology, Pathology,[1] Biomedical Engineering, and Integrative Immunobiology.[2] At the same institution, he held the role of associate deputy director of the Preston Robert Tisch Brain Tumor Center[3] and holds principal investigator's designation.[4] He also co-directed the Duke Center for Brain and Spine Metastasis,[3] and holds the appointments of professor of Neurosurgery and Pathology there.[2] Additionally, in July of 2025, he became chair of the Neurosurgery department at the University of Colorado School of Medicine.[5]
Research
[edit]In a collaborative research, Fecci conducted an immunocompetent study with an emphasis on lung adenocarcinoma and observed that TIM-3 expression significantly contributed to tumor relapse after anti-PD-1 treatment.[6] He also demonstrated that the activated epidermal growth factor receptor (EGFR) pathway promoted immune escape by increasing the levels of PD-1 and PD-L1.[7] Additionally, he examined the presence of STK11/LKB1 in KRas-mutated tumors, determining that it lowers PD-L1 levels, reduces T-cell infiltration, and increases T-cell exhaustion markers.[8]
Fecci highlighted that both CD4+ T cells[9] and Th cells are reduced in murine glioma models; however, Tregs account for a disproportionately large portion within the CD4 population.[10] He emphasized that dexamethasone reduces T cell proliferation and increases cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cell surfaces.[11] In a group study, he identified that glioblastoma induced T cell dysfunction[12] and categorized it into exhaustion, senescence, anergy, tolerance,[13] and ignorance.[14]
Awards and honors
[edit]- 2013 – Synaptive Preuss Award, American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS)[15]
- 2015 – Sontag Distinguished Scientist Award, Sontag Foundation[1]
- 2016 – Prince Mahidol Youth Mentor Award, Prince Mahidol Award Foundation[16]
Selected articles
[edit]- Fecci, P. E.; Mitchell, D. A.; Whitesides, J. F.; Xie, W.; Friedman, A. H.; Archer, G. E.; et al. (2006). "Increased regulatory T‑cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma". Cancer Research. 66 (6): 3294–3302. doi:10.1158/0008-5472.CAN-05-3773. PMID 16540683.
- Akbay, E. A.; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, C. L.; Wong, K. K.; et al. (2013). "Activation of the PD‑1 pathway contributes to immune escape in EGFR‑driven lung tumors". Cancer Discovery. 3 (12): 1355–1363. doi:10.1158/2159-8290.CD-13-0310. PMC 3864135. PMID 24078774.
- Koyama, S.; Akbay, E. A.; Li, Y. Y.; Herter‑Sprie, G. S.; Buczkowski, K. A.; Richards, W. G.; Hammerman, P. S.; et al. (2016). "Adaptive resistance to therapeutic PD‑1 blockade is associated with upregulation of alternative immune checkpoints". Nature Communications. 7 10501. Bibcode:2016NatCo...710501K. doi:10.1038/ncomms10501. PMC 4757784. PMID 26883990.
- Koyama, S.; Akbay, E. A.; Li, Y. Y.; Aref, A. R.; Skoulidis, F.; Herter‑Sprie, G. S.; Wong, K. K.; et al. (2016). "STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T‑cell activity in the lung tumor microenvironment". Cancer Research. 76 (5): 999–1008. doi:10.1158/0008-5472.CAN-15-1439. PMC 4775354. PMID 26833127.
- Sampson, J. H.; Gunn, M. D.; Fecci, P. E.; Ashley, D. M. (2020). "Brain immunology and immunotherapy in brain tumours". Nature Reviews Cancer. 20 (1): 12–25. doi:10.1038/s41568-019-0224-7. PMC 7327710. PMID 31806885.
References
[edit]- ^ a b c "Peter Fecci". The Sontag Foundation. Retrieved July 15, 2025.
- ^ a b "Peter Edward Fecci". Neurosurgery, Duke University. Retrieved July 25, 2025.
- ^ a b "Peter Fecci named associate deputy director of the Preston Robert Tisch Brain Tumor Center at Duke". Duke Department of Neurosurgery. 16 April 2018. Retrieved July 15, 2025.
- ^ "The Preston Robert Tisch Brain Tumor Center". Preston Robert Tisch Brain Tumor Center at Duke. Retrieved July 15, 2025.
- ^ "Peter E. Fecci, MD, PhD, named chair of the Department of Neurosurgery". CU Anschutz News. Retrieved July 15, 2025.
- ^ Sharma, Padmanee; Hu-Lieskovan, Siwen; Wargo, Jennifer A.; Ribas, Antoni (2017). "Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy". Cell. 168 (4): 707–723. doi:10.1016/j.cell.2017.01.017. PMC 5391692. PMID 28187290.
- ^ Zhu, Shaoming; Zhang, Tian; Zheng, Lei; Liu, Hongtao; Song, Wenru; Liu, Delong; Li, Zihai; Pan, Chong-Xian (2021). "Combination strategies to maximize the benefits of cancer immunotherapy". Journal of Hematology & Oncology. 14 (1): 156. doi:10.1186/s13045-021-01164-5. PMC 8475356. PMID 34579759.
- ^ Jenkins, Russell W.; Barbie, David A.; Flaherty, Keith T. (2018). "Mechanisms of resistance to immune checkpoint inhibitors". British Journal of Cancer. 118 (1): 9–16. doi:10.1038/bjc.2017.434. PMC 5765236. PMID 29319049.
- ^ Chen, Dan; Varanasi, Siva Karthik; Hara, Toshiro; Traina, Kacie; Sun, Ming; McDonald, Bryan; Farsakoglu, Yagmur; Clanton, Josh; Xu, Shihao; Garcia-Rivera, Lizmarie; Mann, Thomas H.; Du, Victor; Chung, H. Kay; Xu, Ziyan; Tripple, Victoria; Casillas, Eduardo; Ma, Shixin; O'Connor, Carolyn; Yang, Qiyuan; Zheng, Ye; Hunter, Tony; Lemke, Greg; Kaech, Susan M. (2023). "CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma". Immunity. 56 (9): 2086–2104.e8. doi:10.1016/j.immuni.2023.07.015. PMC 11800830. PMID 37572655.
- ^ Quail, Daniela F.; Joyce, Johanna A. (2017). "The Microenvironmental Landscape of Brain Tumors". Cancer Cell. 31 (3): 326–341. doi:10.1016/j.ccell.2017.02.009. PMC 5424263. PMID 28292436.
- ^ Pearson, Joshua R. D.; Cuzzubbo, Stefania; McArthur, Simon; Durrant, Lindy G.; Adhikaree, Jason; Tinsley, Chris J.; Pockley, A. Graham; McArdle, Stephanie E. B. (2020). "Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment". Frontiers in Immunology. 11: 582106. doi:10.3389/fimmu.2020.582106. PMC 7594513. PMID 33178210.
- ^ Zhang, Zhiqi; Xu, Xiaoxuan; Du, Jiawei; Chen, Xin; Xue, Yonger; Zhang, Jianqiong; Yang, Xue; Chen, Xiaoyuan; Xie, Jinbing; Ju, Shenghong (2024). "Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy". Nature Communications. 15 (1): 1118. Bibcode:2024NatCo..15.1118Z. doi:10.1038/s41467-024-44963-3. PMC 10847518. PMID 38320994.
- ^ Sharma, Pratibha; Aaroe, Ashley; Liang, Jiyong; Puduvalli, Vinay K. (2023). "Tumor microenvironment in glioblastoma: Current and emerging concepts". Neuro-Oncology Advances. 5 (1): vdad009. doi:10.1093/noajnl/vdad009. PMC 10034917. PMID 36968288.
- ^ Hu, Ankang; Sun, Li; Lin, Hao; Liao, Yuheng; Yang, Hui; Mao, Ying (2024). "Harnessing innate immune pathways for therapeutic advancement in cancer". Signal Transduction and Targeted Therapy. 9 (1): 68. doi:10.1038/s41392-024-01765-9. PMC 10961329. PMID 38523155.
- ^ "Synaptive Preuss Award recipients". Congress of Neurological Surgeons – Tumor Section. Retrieved July 22, 2025.
- ^ "Peter Edward Fecci". Fitzpatrick Institute for Photonics. Retrieved July 15, 2025.
External links
[edit]- Peter Fecci publications indexed by Google Scholar